

**Question for written answer E-001443/2023/rev.1  
to the Commission**

Rule 138

**Mónica Silvana González (S&D)**

**Subject:** EU-Latin America and Caribbean partnership on local manufacturing of vaccines, medicines and other health technologies, and strengthening health system resilience

As a flagship project of the EU's Global Gateway strategy, the EU and the countries of Latin America and the Caribbean (LAC) are aiming to boost LAC's manufacturing capacity for vaccines, medicines and other health technologies, and to strengthen the resilience of its health systems. Despite regional efforts and initiatives, Latin America has moved backwards in the past decade regarding the vaccination of children under five. This makes the EU-LAC partnership on the local manufacturing of vaccines and medicines even more crucial to address the gaps in the region's healthcare systems.

1. How will the partnership address regulatory frameworks and the enabling environment for sustainability, and what measures will be put in place to ensure equitable access to quality healthcare products in LAC?
2. How will the partnership be applied in regions where private companies have a stronger presence than the public sector, and how will European enterprises tackle the World Trade Organization restrictions regarding compulsory licensing?
3. In terms of quantity, what volume of vaccine production is to be expected?

Submitted:3.5.2023